Tower View Wealth Management LLC Decreases Stock Holdings in Eli Lilly and Company $LLY

Tower View Wealth Management LLC lessened its holdings in Eli Lilly and Company (NYSE:LLY) by 5.3% during the first quarter, HoldingsChannel reports. The institutional investor owned 9,670 shares of the company’s stock after selling 542 shares during the quarter. Eli Lilly and Company comprises 4.6% of Tower View Wealth Management LLC’s investment portfolio, making the stock its 4th biggest position. Tower View Wealth Management LLC’s holdings in Eli Lilly and Company were worth $8,894,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Dorsey Wright & Associates purchased a new position in Eli Lilly and Company during the first quarter worth about $468,000. Fiduciary Alliance LLC raised its holdings in shares of Eli Lilly and Company by 5.2% in the 1st quarter. Fiduciary Alliance LLC now owns 10,807 shares of the company’s stock valued at $9,781,000 after acquiring an additional 536 shares in the last quarter. Kestra Private Wealth Services LLC boosted its position in shares of Eli Lilly and Company by 5.4% during the 1st quarter. Kestra Private Wealth Services LLC now owns 54,306 shares of the company’s stock valued at $49,949,000 after acquiring an additional 2,781 shares during the last quarter. Chatterton & Associates Inc. grew its holdings in shares of Eli Lilly and Company by 14.1% during the first quarter. Chatterton & Associates Inc. now owns 557 shares of the company’s stock worth $532,000 after purchasing an additional 69 shares in the last quarter. Finally, Arta Finance Wealth Management LLC grew its holdings in shares of Eli Lilly and Company by 4.4% during the first quarter. Arta Finance Wealth Management LLC now owns 405 shares of the company’s stock worth $373,000 after purchasing an additional 17 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Up 7.0%

LLY opened at $1,206.51 on Friday. The company has a market cap of $1.14 trillion, a P/E ratio of 42.86, a P/E/G ratio of 1.23 and a beta of 0.53. The business’s 50-day moving average price is $1,036.28 and its 200-day moving average price is $1,020.95. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,215.76.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, beating the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company had revenue of $19.80 billion during the quarter, compared to analysts’ expectations of $17.82 billion. During the same period in the prior year, the business posted $3.34 EPS. Eli Lilly and Company’s quarterly revenue was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, equities analysts expect that Eli Lilly and Company will post 35.8 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio is currently 24.58%.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The European Medicines Agency’s CHMP recommended approval of Jaypirca (pirtobrutinib) for adults with chronic lymphocytic leukemia across all lines of therapy, which could expand Lilly’s oncology revenue opportunity in the EU. Article Title
• Positive Sentiment: Investors are also focused on Lilly’s obesity franchise, with new details on the Medicare GLP-1 Bridge program that could broaden access to Foundayo (orforglipron) and Zepbound for eligible Medicare Part D patients starting July 1. Article Title
• Positive Sentiment: Management’s expanded access push and continued clinical progress in obesity/diabetes are reinforcing the view that Lilly remains a leader in the weight-loss drug race, supporting bullish sentiment. Article Title
• Neutral Sentiment: Some recent coverage highlights Lilly’s strong pipeline and market leadership, but also notes valuation concerns and a less attractive entry point after the stock’s big run. Article Title
• Neutral Sentiment: News about Lilly launching its cancer drug Tanstrive in India adds another growth angle, but it appears to be a smaller near-term stock driver than the obesity and EU approval updates. Article Title

Analysts Set New Price Targets

LLY has been the topic of several research analyst reports. Wolfe Research restated an “outperform” rating and issued a $1,350.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, May 21st. Berenberg Bank boosted their price target on shares of Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the stock a “hold” rating in a research note on Monday, June 22nd. Royal Bank Of Canada reissued an “outperform” rating on shares of Eli Lilly and Company in a report on Thursday, May 21st. Sanford C. Bernstein restated an “outperform” rating on shares of Eli Lilly and Company in a research report on Monday, June 8th. Finally, Bank of America lifted their price objective on shares of Eli Lilly and Company from $1,133.00 to $1,251.00 and gave the stock a “buy” rating in a report on Tuesday, May 26th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $1,235.07.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.